Iridex (IRIX) Cash from Financing Activities (2011 - 2026)
Iridex's (IRIX) quarterly Cash from Financing Activities came in at -$1000.0 in Q2 2026, down 100.02% year-on-year from $6.0 million in Q2 2025, and up 96.3% quarter-over-quarter from -$27000.0 in Q1 2026.
Iridex (IRIX) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Iridex's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$1000.0 for Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 100.02% year-over-year to -$1000.0 in Q2 2026; TTM through Apr 2026 was -$76000.0, a 100.88% decrease from a year earlier, with the FY2026 full-year figure at $6.0 million, up 128.94% from the prior year.
- Cash from Financing Activities climbed to -$1000.0 in Q2 2026 per IRIX's latest filing, from -$27000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.0 million in Q1 2022 and bottomed at -$218000.0 in Q4 2024.
- The 5-year median for Cash from Financing Activities is -$14000.0 (2025), against an average of $1.0 million.
- Biggest YoY gain for Cash from Financing Activities was 11862.5% in 2024; the steepest drop was 584.44% in 2024.
- Year by year, Cash from Financing Activities stood at -$26000.0 in 2022, then soared by 273.08% to $45000.0 in 2023, then tumbled by 584.44% to -$218000.0 in 2024, then jumped by 84.4% to -$34000.0 in 2025, then soared by 97.06% to -$1000.0 in 2026.
- Per Business Quant, the three latest IRIX Cash from Financing Activities figures stand at -$1000.0 (Q2 2026), -$27000.0 (Q1 2026), and -$34000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Iridex | 15.93 Mn | 11.33 Mn | 4.74 Mn | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 4, 2026 | -1,000.00 |
| Apr 4, 2026 | -1,000.00 |
| Jan 3, 2026 | -27,000.00 |
| Jan 3, 2026 | -27,000.00 |
| Sep 27, 2025 | -34,000.00 |
| Sep 27, 2025 | -34,000.00 |
| Jun 28, 2025 | -14,000.00 |
| Jun 28, 2025 | -14,000.00 |
| Mar 29, 2025 | 6.04 Mn |
| Mar 29, 2025 | 6.04 Mn |
| Dec 28, 2024 | -218,000.00 |
| Dec 28, 2024 | -218,000.00 |
| Sep 28, 2024 | 2.82 Mn |
| Sep 28, 2024 | 2.82 Mn |
| Dec 30, 2023 | 45,000.00 |
| Dec 30, 2023 | 45,000.00 |
| Sep 30, 2023 | -24,000.00 |
| Sep 30, 2023 | -24,000.00 |
| Jul 1, 2023 | -63,000.00 |
| Jul 1, 2023 | -63,000.00 |